Russell 2000 Surges 20% as Investors Pivot from Mega-Caps
U.S. small-cap stocks are outperforming large-cap indices in 2026 as investors reduce concentration risk and capitalize on a persistent valuation discount.
The Russell 2000 has risen approximately 20% year-to-date in 2026, overtaking the S&P 500 and marking a decisive shift after years of trailing large-cap indices. This breakout performance signals that market participation is broadening beyond a narrow cluster of dominant technology names.
For institutional and retail investors, this movement addresses a critical portfolio vulnerability: overexposure to artificial intelligence-driven mega-caps. Rather than signaling a fundamental rejection of the AI trade, the small-cap rally represents a strategic de-risking. Market participants are actively broadening their exposure to mitigate concentration risk while still capturing equity upside.
A key driver of this rotation is the persistent valuation discount embedded in smaller companies. Even after a strong 2026 run, small-cap ETFs trade at roughly 16 times earnings compared to the 21 times multiple commanded by large-cap equivalents. Specifically, the SPDR S&P 500 ETF (SPY) currently trades at a 20.95x price-to-earnings ratio and a 4.56x price-to-book ratio.
By comparison, the Vanguard Small-Cap ETF (VB) presents a cheaper entry point at a 17.43x earnings multiple and a 2.43x book multiple. This structural price gap suggests the sector still offers a margin of safety for capital continuing to rotate out of overvalued large caps.
To access this trend, market professionals typically weigh two distinct, low-cost funds. The SPDR Portfolio S&P 600 Small Cap ETF (SPSM) applies a strict profitability screen to its holdings and charges a minimal 0.03% expense ratio. Conversely, the Vanguard Small-Cap ETF (VB) opts for sheer breadth over profitability filters, charging a 0.05% fee.
VB tracks the CRSP U.S. Small Cap Index, spreading capital across more than 1,300 companies. Its current leading positions include Credo Technology Group, Jabil Inc (JBL), and Revolution Medicines, Inc (RVMD). This level of diversification positions the fund as a straightforward core holding for broad market exposure.
Furthermore, VB's 2026 performance undermines the historical narrative of punitive small-cap volatility. With a current Sharpe ratio of 1.42 and a Sortino ratio of 2.09, the fund demonstrates that investors have been highly compensated for the incremental risk associated with the asset class during this rally.
